Arthur C. Santora II - Sep 7, 2022 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role: Chief Medical Officer
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Stock symbol: ENTX
Transactions as of: Sep 7, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/9/2022, 04:09 PM
Previous filing: Jan 14, 2022
Next filing: Apr 25, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTX	Stock Option (right to buy)	Award	$0	+20K		$0.00	20K	Sep 7, 2022	Ordinary Shares, par value NIS 0.0000769 per share	20K	$2.86	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This grant of options was approved by the Board of Directors of Entera Bio Ltd. (the "Company") on March 31, 2021, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on March 31, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

Content

This grant of options was approved by the Board of Directors of Entera Bio Ltd. (the "Company") on March 31, 2021, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on March 31, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.